165 results on '"Cremona, Mattia"'
Search Results
2. Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors
3. Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
4. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
5. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
6. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
7. Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea
8. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
9. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
10. Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors
11. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
12. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
13. Supplementary Methods SM3 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
14. Supplementary Table ST1 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
15. Supplementary Figure S2 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
16. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11 /Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
17. Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
18. A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
19. BCL-2 system analysis identifies high-risk colorectal cancer patients
20. Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression
21. Abstract 1386: The role of MDM2 inhibition in the radiosensitization of ER+ breast cancers
22. Additional file 1 of Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
23. Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell Lines
24. Stratification of clear cell renal cell carcinoma by signaling pathway analysis
25. AMPK‐regulated miRNA‐210‐3p is activated during ischaemic neuronal injury and modulates PI3K‐p70S6K signalling
26. Additional file 1 of Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
27. Additional_File_1___Cell_line_authentication – Supplemental material for Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
28. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
29. Clinical Proteomics and Molecular Pathology
30. List of Contributors
31. Abstract 6270: A radiosensitizer screen identifies a novel role for MDM2 inhibition in the radiosensitization of ER+ breast cancers in a p53 dependent manner
32. Systems analysis of protein signatures predicting cetuximab responses inKRAS,NRAS,BRAFandPIK3CAwild‐type patient‐derived xenograft models of metastatic colorectal cancer
33. Abstract P3-06-01: Junctional adhesion molecule-A (JAM-A) as a novel future drug target in ductal carcinomain situ(DCIS)
34. Preclinical drug testing for clinical trial planning of novel combinative therapy with PI3K and MAPK inhibitors in colorectal cancer(CRC).
35. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
36. Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea
37. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk
38. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
39. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitroand in vivo
40. Supplementary_material – Supplemental material for Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
41. Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate
42. Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)
43. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer.
44. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
45. Abstract 4627: Integrated multi-layer analysis reveals novel insights into the molecular landscape of colorectal cancer (CRC)
46. Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
47. Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
48. Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
49. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
50. A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.